109 related articles for article (PubMed ID: 25075421)
1. [Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].
Ivanova SA; Losenkov IS; Bokhan NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):93-100. PubMed ID: 25075421
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
Cole AR
FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
[TBL] [Abstract][Full Text] [Related]
3. Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders.
Serretti A; Benedetti F; Mandelli L; Calati R; Caneva B; Lorenzi C; Fontana V; Colombo C; Smeraldi E
Psychiatry Res; 2008 Mar; 158(2):132-40. PubMed ID: 17976739
[TBL] [Abstract][Full Text] [Related]
4. Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-β activity.
Benedetti F; Poletti S; Radaelli D; Bernasconi A; Cavallaro R; Falini A; Lorenzi C; Pirovano A; Dallaspezia S; Locatelli C; Scotti G; Smeraldi E
Genes Brain Behav; 2010 Jun; 9(4):365-71. PubMed ID: 20113358
[TBL] [Abstract][Full Text] [Related]
5. GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.
Tang H; Shen N; Jin H; Liu D; Miao X; Zhu LQ
Mol Neurobiol; 2013 Dec; 48(3):404-11. PubMed ID: 23440732
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
Manduca JD; Thériault RK; Perreault ML
Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
[TBL] [Abstract][Full Text] [Related]
7. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD; Picchini AM; Einat H; Manji HK
Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
[TBL] [Abstract][Full Text] [Related]
8. The role of glycogen synthase kinase-3beta in schizophrenia.
Koros E; Dorner-Ciossek C
Drug News Perspect; 2007 Sep; 20(7):437-45. PubMed ID: 17992266
[TBL] [Abstract][Full Text] [Related]
9. GSK3B and schizophrenia: a case not closed.
Sand PG; Domani M; Smesny S
Psychopharmacology (Berl); 2010 Feb; 208(2):333-4; author reply 335-6. PubMed ID: 19936977
[No Abstract] [Full Text] [Related]
10. Association of GSK-3β genetic variation with GSK-3β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia.
Blasi G; Napolitano F; Ursini G; Di Giorgio A; Caforio G; Taurisano P; Fazio L; Gelao B; Attrotto MT; Colagiorgio L; Todarello G; Piva F; Papazacharias A; Masellis R; Mancini M; Porcelli A; Romano R; Rampino A; Quarto T; Giulietti M; Lipska BK; Kleinman JE; Popolizio T; Weinberger DR; Usiello A; Bertolino A
Am J Psychiatry; 2013 Aug; 170(8):868-76. PubMed ID: 23598903
[TBL] [Abstract][Full Text] [Related]
11. Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder.
Szczepankiewicz A; Skibinska M; Hauser J; Slopien A; Leszczynska-Rodziewicz A; Kapelski P; Dmitrzak-Weglarz M; Czerski PM; Rybakowski JK
Neuropsychobiology; 2006; 53(1):51-6. PubMed ID: 16397405
[TBL] [Abstract][Full Text] [Related]
12. Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia.
Scassellati C; Bonvicini C; Perez J; Bocchio-Chiavetto L; Tura GB; Rossi G; Racagni G; Gennarelli M
Neuropsychobiology; 2004; 50(1):16-20. PubMed ID: 15179015
[TBL] [Abstract][Full Text] [Related]
13. Schizophrenia as a GSK-3 dysregulation disorder.
Lovestone S; Killick R; Di Forti M; Murray R
Trends Neurosci; 2007 Apr; 30(4):142-9. PubMed ID: 17324475
[TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
Pandey GN; Ren X; Rizavi HS; Dwivedi Y
J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
[TBL] [Abstract][Full Text] [Related]
15. Neurodevelopment and mood stabilizers.
Harwood AJ
Curr Mol Med; 2003 Aug; 3(5):472-82. PubMed ID: 12943000
[TBL] [Abstract][Full Text] [Related]
16. Altered Wnt signalling in the teenage suicide brain: focus on glycogen synthase kinase-3β and β-catenin.
Ren X; Rizavi HS; Khan MA; Dwivedi Y; Pandey GN
Int J Neuropsychopharmacol; 2013 Jun; 16(5):945-55. PubMed ID: 23110823
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
18. Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate.
Twomey C; McCarthy JV
FEBS Lett; 2006 Jul; 580(17):4015-20. PubMed ID: 16814287
[TBL] [Abstract][Full Text] [Related]
19. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications.
Gould TD
Expert Opin Ther Targets; 2006 Jun; 10(3):377-92. PubMed ID: 16706678
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.
Desbois-Mouthon C; Blivet-Van Eggelpoël MJ; Beurel E; Boissan M; Delélo R; Cadoret A; Capeau J
Hepatology; 2002 Dec; 36(6):1528-36. PubMed ID: 12447879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
